Dr Martin Treder | Chief Scientific Officer
Affimed Therapeutics Ag

Dr Martin Treder, Chief Scientific Officer, Affimed Therapeutics Ag

Dr. Treder joined Affimed’s Management Team in 2015. He has a strong track record in preclinical and clinical biotherapeutic research and development, having established a broad research pipeline of programs in targeted cancer therapy and immuno-oncology. Dr. Treder has more than 15 years of professional experience including as co-founder and Chief Scientific Officer of CT Atlantic AG and co-founder of U3 Pharma AG.
Dr. Treder graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the University of Würzburg, Germany. He earned his PhD working in Prof. Axel Ullrich's group at the Max Planck Institute of Biochemistry in Martinsried-Munich, Germany.


WIC 2017 Day 1, Tuesday 31st October 2017 @ 14:50

Development of innate cell engagers for effective anti-tumor targeting

  • Affimed develops tetravalent, bispecific immuno-engagers for tumor-targeting of T-cells and NK-cells based on proprietary scaffolds and engager domains
  • Potency and efficacy of several immuno-engagers are currently being evaluated in clinical mono and combination trials
  • Recent developments from our NK-cell engager platform demonstrating superior efficacy over conventional Fc-based approaches will be presented

back to speakers